Thu, Mar 5, 2015, 8:20 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Celgene Corp. (CELG) Message Board

pkornie 81 posts  |  Last Activity: 1 hour 12 minutes ago Member since: Apr 24, 2007
  • Reply to

    NASH data

    by selectmpsa Apr 16, 2010 5:54 PM
    pkornie@sbcglobal.net pkornie 1 hour 12 minutes ago Flag

    Re: GILDYxxxXx..APWR.o.

    Don'tThinkSo.

    o.

    .

    Sentiment: Strong Buy

  • Reply to

    Re: Re: Mutted response

    by pkornie Apr 17, 2010 12:28 PM
    pkornie@sbcglobal.net pkornie 1 hour 22 minutes ago Flag

    Re: WhereIsSusan.
    Reply to Re: Re: Mutted response by pkornie •Apr 17, 2010 12:28 PM.
    .
    pkornie • Apr 21, 2010 8:39 PM Remove
    0
    users liked this posts
    users disliked this posts
    0
    Reply
    .

    (__o__) / (_I_) / .(___O___).

    (

    o.
    http://finance.yahoo.com/mb/forumview/?&bn=604616e4-d592-3744-a14e-c3ff33204dec&f=0#

    .

    Sentiment: Strong Buy

  • Reply to

    NASH data

    by selectmpsa Apr 16, 2010 5:54 PM
    pkornie@sbcglobal.net pkornie 1 hour 34 minutes ago Flag

    o.

    When'sDaSp.

    o..

    .

    Sentiment: Strong Buy

  • Reply to

    NASH data

    by selectmpsa Apr 16, 2010 5:54 PM
    pkornie@sbcglobal.net pkornie 1 hour 37 minutes ago Flag

    Re: Questions.

    o.

    .

    Sentiment: Strong Buy

  • Reply to

    Dead cat bounce...suckers. Now I'm pissed

    by darrellkwerth Nov 5, 2009 11:00 AM
    pkornie@sbcglobal.net pkornie 1 hour 42 minutes ago Flag

    Re: One of lalala most active after hours.

    o.

    .

    Sentiment: Strong Buy

  • Reply to

    Re: Busted.

    by pkornie Apr 16, 2010 3:43 PM
    pkornie@sbcglobal.net pkornie 2 hours 9 minutes ago Flag

    re: tgigolos
    1 post | Last Activity: 44 minutes ago
    Member since: Mar 5, 2015

    o.

    .

    Sentiment: Strong Buy

  • Reply to

    Re:-OlooksLikeShe/he.... wanted(&.

    by pkornie Feb 9, 2015 5:16 PM
    pkornie@sbcglobal.net pkornie Mar 4, 2015 11:51 AM Flag

    Re: dorthyhossackrjd
    15 posts | Last Activity: 7 hours ago
    Member since: Mar 4, 2015

    o.

    .

    Sentiment: Strong Buy

  • Reply to

    Re:-OlooksLikeShe/he.... wanted(&.

    by pkornie Feb 9, 2015 5:16 PM
    pkornie@sbcglobal.net pkornie Mar 4, 2015 10:15 AM Flag

    OwhereIsSusan.

    o.

    .

    Sentiment: Strong Buy

  • pkornie@sbcglobal.net by pkornie Feb 28, 2015 4:29 AM Flag

    Topic hidden because you ignored this user

    Show Post

    Sentiment: Strong Buy

  • Reply to

    Dead cat bounce...suckers. Now I'm pissed

    by darrellkwerth Nov 5, 2009 11:00 AM
    pkornie@sbcglobal.net pkornie Feb 28, 2015 1:01 AM Flag

    Re: FAQ. JusB(Buy)GILTY.FORGETaboutIT.

    o.

    .

    Sentiment: Strong Buy

  • Reply to

    Dead cat bounce...suckers. Now I'm pissed

    by darrellkwerth Nov 5, 2009 11:00 AM
    pkornie@sbcglobal.net pkornie Feb 28, 2015 12:49 AM Flag

    Re: WhereIsSusan.

    o.

    .

    pkornie • Apr 15, 2010 9:54 AM Remove

    0
    users liked this posts

    users disliked this posts
    0
    Reply
    .

    Btripla- Quad).

    Study 102 evaluates Quad versus Atripla in 700 naïve HIV patients (randomized 1:1) over 96 weeks at 130 sites in the U.S. and Puerto Rico. Study 103 evaluates Quad versus Truvada+Reyataz+ritonavir (a popular regimen outside of the U.S.) in 700 naïve HIV patients (randomized 1:1) also over 96 weeks at more than 200 sites in North and South America, Europe and Asia Pacific.

    The primary endpoint of both studies is the proportion of patients achieving a HIV Ribonucleic acid level less than 50 copies/milliliter at 48 weeks. Secondary endpoints include efficacy, safety and tolerability though 96 weeks. After week 96, patients will be given the option to participate in the open-label extension phase for Quad.

    Gilead is expected to report first-quarter results after market close on April 20. We are raising our first-quarter revenue estimate from $1.938 billion to $2.063 billion versus consensus of $2.049 billion, and GAAP earnings per share from 82 cents to 90 cents versus consensus of 87 cents, mostly due to adjustments on the contracts and royalties line. We have raised our first-quarter contracts and royalties estimate from $83 million to $208 million, after adjusting the Tamiflu royalties for the quarter based on Roche's reported fourth-quarter Tamiflu sales. Less

    o.

    .

    Sentiment: Strong Buy

  • Reply to

    Dead cat bounce...suckers. Now I'm pissed

    by darrellkwerth Nov 5, 2009 11:00 AM
    pkornie@sbcglobal.net pkornie Feb 27, 2015 11:47 AM Flag

    Re: wtrayah
    1 post | Last Activity: 47 minutes ago
    Member since: Feb 27, 2015

    o.

    .

    Sentiment: Strong Buy

  • Reply to

    Dead cat bounce...suckers. Now I'm pissed

    by darrellkwerth Nov 5, 2009 11:00 AM
    pkornie@sbcglobal.net pkornie Feb 26, 2015 10:03 PM Flag

    Re:
    cd3313 • 44 minutes ago Flag

    2
    users liked this posts

    users disliked this posts
    0
    Reply

    .

    Enough already, with your personal vendettas and posts designed to impress us with your access to insider information.
    Then again, enough already too with all the whining, crying posts about how everything else is going up and GILD's a stale POS.

    JUST MOVE ON!!!!!

    Nobody is forcing anyone to hold shares in this Company.

    Just because pkornie got a couple of "thumbs up" today and probably has more money in the bank than most of the posters here, that doesn't mean GILD's going to double every year.

    The problem is, you all get greedy because you recognize Gilead's potential.
    But, you don't have pkornie's patience to see it through.

    LONG AND STRONG Less

    Sentiment: Strong Buy

    DatsRight....$400k/yr ~ LongTermIsOK.

    When'sDaSp.

    o.

    ..

    Sentiment: Strong Buy

  • Reply to

    Dead cat bounce...suckers. Now I'm pissed

    by darrellkwerth Nov 5, 2009 11:00 AM
    pkornie@sbcglobal.net pkornie Feb 26, 2015 5:44 PM Flag

    Re: Reply to Th media is relentless negative on GILD.

    It'sLikDis.IgotMineAndIbuyTheDips.

    o.

    .

    Sentiment: Strong Buy

  • Reply to

    Dead cat bounce...suckers. Now I'm pissed

    by darrellkwerth Nov 5, 2009 11:00 AM
    pkornie@sbcglobal.net pkornie Feb 25, 2015 10:05 PM Flag

    Re: http://finance.yahoo.com/mbview/threadview/;_ylt=AsdDFQLSxTBfVYnqWpv8qQPeAohG;_ylu=X3oDMTB1cDZkbG52BHBvcwM4BHNlYwNNZWRpYU1zZ0JvYXJkc1hIUlVsdA--;_ylg=X3oDMTBhYWM1a2sxBGxhbmcDZW4tVVM-;_ylv=3?&bn=604616e4-d592-3744-a14e-c3ff33204dec&tid=1391785872836-754c633d-3ac2-4653-b5f2-307de2de9068

    o.

    .

    Sentiment: Strong Buy

  • Reply to

    Cost of ACHN went up this morning

    by buy_n_hold_2001 Mar 18, 2010 8:14 AM
    pkornie@sbcglobal.net pkornie Feb 25, 2015 9:46 PM Flag

    Re: Ambrisentan.

    o.

    .

    Sentiment: Strong Buy

  • Reply to

    Re: Tell your Broker you'll put it at 159 then?

    by pkornie Feb 25, 2015 2:33 PM
    pkornie@sbcglobal.net pkornie Feb 25, 2015 9:38 PM Flag

    Re: GoodCompany.CaresForShareHolders,

    25-Nov-14 Ex-Date for dividend payment of $0.48 .

    WhensDaSp.

    Sentiment: Strong Buy

  • Reply to

    Dead cat bounce...suckers. Now I'm pissed

    by darrellkwerth Nov 5, 2009 11:00 AM
    pkornie@sbcglobal.net pkornie Feb 25, 2015 9:11 PM Flag

    Re:

    0
    Reply
    .

    Re: NoticeTheyDoNotHaveAny(H1N1)news.
    YourFaceLooksLikA Virally Suppressed Monkeys'
    Gilead Announces Preclinical Data for an Investigational TLR7 Agonist in SIV-Infected, Virally Suppressed Monkeys
    – Data Support Plans for Phase 2 Clinical Trial in Humans –
    ... More

    Sentiment: Strong Buy

    Sentiment: Strong Buy

  • Reply to

    Dead cat bounce...suckers. Now I'm pissed

    by darrellkwerth Nov 5, 2009 11:00 AM
    pkornie@sbcglobal.net pkornie Feb 25, 2015 9:01 PM Flag

    Re: NoticeTheyDoNotHaveAny(H1N1)news.
    YourFa. Virally Suppressed Monkeys

    Gilead Announces Preclinical Data for an Investigational TLR7 Agonist in SIV-Infected, Virally Suppressed Monkeys
    – Data Support Plans for Phase 2 Clinical Trial in Humans –
    SEATTLE--(BUSINESS WIRE)--Feb. 25, 2015-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced results from a preclinical study conducted in collaboration with researchers at Beth Israel Deaconess Medical Center evaluating a proprietary investigational oral toll-like receptor 7 (TLR7) agonist and analogue of GS-9620 as part of an HIV eradication strategy. Data demonstrate that treatment with the TLR7 agonist induced transient plasma Simian Immunodeficiency Virus (SIV) RNA, as well as reduced SIV DNA in virally suppressed rhesus macaques given antiretroviral therapy (ART). In addition, the study found that after discontinuation of ART, SIV viral loads were lower among macaques that received the proprietary TLR7 agonist compared to the placebo group. These data were presented in an oral session (Session O-9) at the 22nd Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
    “One reason current therapies can’t cure HIV is that latent reservoirs of the virus persist even among individuals who are virally suppressed on ART,” said James Whitney, PhD, Assistant Professor of Medicine, Harvard Medical School, and study Principal Investigator in the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston. Dr. Whitney is also an Associate Member of The Ragon Institute of MGH, MIT and Harvard, which was founded in 2009 to contribute to the accelerated discovery of an HIV/AIDS vaccine and to establish itself as a world leader in the collaborative study of immunology. “These data demonstrate that, given alongside ART, the TLR7 agonist may have the potential to both stimulate virus production and eliminate latently infected cells – an eradication strategy being explored today.”

    Sentiment: Strong Buy

  • NoGoAhead.

    o.

    .

    Sentiment: Strong Buy

CELG
120.71+1.14(+0.95%)Mar 5 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Geron Corporation
NASDAQThu, Mar 5, 2015 4:00 PM EST
Orexigen Therapeutics, Inc.
NASDAQThu, Mar 5, 2015 4:00 PM EST
Orbital ATK, Inc.
NYSEThu, Mar 5, 2015 4:02 PM EST